TCblR Modulators for Cobalamin Uptake Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively preventing and treating cobalamin deficiency, as well as managing diseases related to cell proliferation, immune responses, and inflammation, due to limited understanding and characterization of the transcobalamin receptor (TCblR) and its role in cobalamin uptake.
Innovation Solution
The development of novel TCblR polypeptides and polynucleotides, including siRNA and antibodies specific for TCblR, to modulate cobalamin uptake and treat associated diseases by inhibiting or enhancing TCblR expression and activity, thereby regulating cellular uptake and growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to prevent and treat cobalamin deficiency, then treatment is provided, but the treatment is inadequate due to limited understanding and characterization of the transcobalamin receptor
Solution Approach 1:
The patent creates copies of the transcobalamin receptor through cloning its cDNA and expressing the protein in heterologous systems. This allows researchers to study the receptor's structure and function without requiring complex native tissue samples, thereby improving understanding while providing reliable treatment targets
Solution Approach 2:
The patent uses heterologous expression systems as intermediaries to produce the transcobalamin receptor protein. These systems serve as a bridge between the genetic information and functional protein studies, enabling detailed characterization that leads to more effective treatments
2Adaptability or versatility
If novel TCblR modulators are developed to selectively deplete or deliver cobalamin to cells, then targeted treatment of cancer and inflammatory disorders is achieved, but the complexity of the treatment system increases
Solution Approach 1:
The patent develops a universal modulator system based on the transcobalamin receptor that can be adapted for multiple therapeutic applications. The same receptor-targeting approach is used for both cancer treatment (cobalamin depletion) and inflammatory disorders (cobalamin delivery), reducing overall system complexity through a common platform
Solution Approach 2:
The patent achieves targeted treatment by changing the parameters of cobalamin delivery - using the same TCblR-targeting mechanism but varying the cobalamin status (depletion vs. delivery) to treat different disease conditions. This parameter-based differentiation simplifies the overall therapeutic strategy
Data Source
AI summary
The present invention provides the amino acid and polynucleotide sequences of the transcobalamin receptor, as well as modulators of the transcobalamin receptor. Accordingly, the present invention provides compositions and methods for the treatment and prevention of diseases and disorders associated with cobalamin deficiency, including compositions and methods that promote cobalamin uptake. In addition, the present invention provides compositions and methods for the detection, treatment, and prevention of diseases associated with deregulated cell growth, including, e.g., cancer and autoimmune disorders, including compositions and methods that inhibit cobalamin uptake.